Daniel Gattari

Mr. Daniel Gattari

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
SCSusanna Cooper
Susanna Cooper
EDEugene Duvenage
Eugene Duvenage
DGDaniel Gattari
Daniel Gattari
JCJoshua J. Cull
Joshua J. Cull
PDPhilip R. Dash
Philip R. Dash
ACAngela Clerk
Angela Clerk
Background The anti-cancer MEK inhibitor trametinib (alone or with the RAF inhibitor dabrafenib) causes cardiac dysfunction or heart failure in some patients. Our hypothesis is that cardiotoxicity is exacerbated by an underlying co-morbidity such as hypertension causing early cardiac dysfunction detectable on echocardiograms. Objectives The objectives were to assess the effects of trametinib on cardiac function in a mouse model of hypertension-induced cardiac hypertrophy and determine if this was moderated by dabrafenib. Methods Male mice were treated with vehicle, trametinib or dabrafenib/trametinib in the absence/presence of angiotensin II (AngII; 0.8 mg/kg/d to increase blood pressure over 7 d). Hearts were imaged using echocardiography. Results Inhibitors alone had a limited effect on mouse hearts over 28 d. Trametinib or trametinib/dabrafenib inhibited cardiac hypertrophy induced by AngII over 7 d, reducing left ventricular (LV) wall thickness and mass. AngII did not significantly affect cardiac function, but the inhibitors caused significant functional deterioration. Segmental analysis revealed variation of contraction around the LV, with selective effects of AngII and trametinib or dabrafenib/trametinib in basal/mid-regional segments. Frame-by-frame analysis of radial (not longitudinal) displacement of the LV endocardial wall demonstrated variation between consecutive cardiac cycles that enabled a high degree of classification according to treatment. Conclusions Trametinib inhibits AngII-induced cardiac hypertrophy in mice but is detrimental to cardiac function, responses that are not moderated by dabrafenib. AngII and MEK/RAF inhibition have regional effects around the LV with greater effects on radial displacement in basal/mid-regional segments. Assessment of such changes may facilitate early identification of developing cardiotoxicity. Competencies in Medical knowledge The anti-cancer drugs trametinib and dabrafenib are cardiotoxic in some patients. These drugs had limited effects themselves on mouse hearts, but suppressed cardiac hypertrophy in a mouse model of hypertension whilst proving detrimental to cardiac function. Segments around the left ventricle were differentially affected by hypertension and inhibitors,with variation between consecutive cardiac cycles. Translational outlook Further research is needed to establish the relationship between hypertension and cardiotoxicity of trametinib in patients, and determine if regional effects in the ventricle wall can predict cardiac dysfunction. If so, a diagnostic algorithm may be a useful tool in identifying developing cardiotoxicity. Inhibiting ERK1/2 suppresses cardiac fibrosis and cardiomyocyte hypertrophy induced by angiotensin II. This results in a decline in cardiac function, with particular effects on radial wall movement and in different segments of the left ventricle.

31 May 2024
Verified
Book Chapter
Closed access
PDF file
DGDaniel Gattari
Daniel Gattari
DCDebora Chan
Debora Chan
EDEmiliano Diez
Emiliano Diez
MSMariano Llamedo Soria
Mariano Llamedo Soria
MRMario Rossi
Mario Rossi

10 August 2024
Verified
Book Chapter
Closed access
PDF file
DGDaniel Gattari
Daniel Gattari
DCDébora Chan
Débora Chan
EDEmiliano Diez
Emiliano Diez
MSMariano Llamedo Soria
Mariano Llamedo Soria
MRMario Rossi
Mario Rossi

Verified
Journal Article
Open access
PDF file
DGDaniel Gattari
Daniel Gattari
JSJoseba Sancho-Zamora
Joseba Sancho-Zamora
DCDebora Mirta Chan
Debora Mirta Chan
NPNatalia Jorgelina Prado
Natalia Jorgelina Prado
EDEmiliano Diez
Emiliano Diez
MRMario Rossi
Mario Rossi
Connexin-43 (CX43) lateralization in ventricular myocardium has been associated with abnormal impulse propagation and increased arrhythmia susceptibility. Its quantitative assessment in histological sections remains challenging because previous methods require segmentation of individual cardiomyocytes and rely on geometric rules applied to segmented cell profiles. Here, we present CLARISA, a segmentation-free, ROI-based deep learning framework that classifies CX43-positive regions as terminal or lateralized directly from fluorescence images. An expert-annotated dataset was generated from left-ventricular cryosections of Wistar rat hearts, in which CX43-positive regions were labeled according to their distribution pattern. A dual-stream EfficientNetV2-S classifier was trained to capture both local and contextual ROI morphology. We also developed a semi-automated whole-section inference module to generate spatial lateralization probability maps and global percent lateralization estimates. On the held-out test set, CLARISA achieved a ROC-AUC of 0.904 (95% bootstrap CI: 0.828–0.960) and a PR-AUC of 0.808 (95% bootstrap CI: 0.682–0.913), supporting the feasibility of automated ROI classification for CX43 lateralization assessment. When deployed on whole tissue sections, including an independently analyzed section not used during model development, CLARISA generated spatial maps that captured heterogeneous CX43 organization and produced a global percent lateralization estimate closely aligned with expert annotation, differing by only 1.30 percentage points over the same detected CX43-positive area. Comparison with a previously published segmentation-based method further indicated that ROI-based and cell-segmentation-based approaches provide related but non-equivalent readouts of CX43 lateralization. The ROI-based design additionally reduces annotation burden—requiring classification of discrete CX43-positive signal rather than complex cardiomyocyte delineation—and ensures that all detected CX43-positive signal contributes to the lateralization estimate regardless of cell boundaries. These results establish CLARISA as a proof-of-principle framework for scalable, segmentation-free CX43 lateralization assessment in cardiac tissue. Further validation across larger, independent, and more heterogeneous datasets will be required to assess robustness, portability across imaging conditions, and translational applicability. The complete codebase, pretrained model, image data, and expert annotation tool are publicly available.

19 April 2025
Verified
Dataset
Closed access
ACAngela Clerk
Angela Clerk
SCSusanna Te Cooper
Susanna Te Cooper
EDEugene Duvenage
Eugene Duvenage
JCJoshua J Cull
Joshua J Cull
DGDaniel Gattari
Daniel Gattari
WHWilliam Holderbaum
William Holderbaum
BioStudies – one package for all the data supporting a study

2 May 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
DGDaniel Gattari
Daniel Gattari
JSJoseba Sancho-Zamora
Joseba Sancho-Zamora
DCDebora Mirta Chan
Debora Mirta Chan
EDEmiliano Diez
Emiliano Diez
MSMariano Llamedo Soria
Mariano Llamedo Soria
MRMario Rossi
Mario Rossi
Connexin-43 (CX43) lateralization in ventricular myocardium has been associated with abnormal impulse propagation and increased arrhythmia susceptibility. Its quantitative assessment in histological sections remains challenging because of the difficulty of segmenting individual cardiomyocytes and the reliance of previous methods on geometric rules applied to segmented cell profiles. Here, we present CLARISA, a deep learning framework for classifying CX43-positive regions as either terminal or lateralized directly from fluorescence images, without requiring cardiomyocyte segmentation. An expert-annotated dataset was generated from left-ventricular cryosections of Wistar rat hearts, in which CX43-positive regions were labeled according to their distribution pattern. A dual-stream convolutional classifier based on EfficientNetV2-S was trained to capture both the local and contextual morphology of each region. In addition, an inference module applicable to whole tissue sections was developed to generate spatial lateralization probability maps and global percent lateralization estimates consistent with expert annotation. On the test set, CLARISA achieved a ROC-AUC of 0.905 and a PR-AUC of 0.810. These results support the feasibility of automated assessment of CX43 distribution patterns without explicit cardiomyocyte segmentation. The complete codebase is publicly available, together with access to the pretrained model and the image data used in this study. The Hugging Face model card reports the same held-out test metrics and states that the checkpoint is intended to be used with the main repository.